Human Microbiome Market
Human Microbiome Market Size, Share and Industry Analysis Report By Product (Probiotics, Prebiotics, Medical Foods, Diagnostic Tests, Drugs, Supplements, Symbiotics and Others); By Application (Therapeutics, Diagnostics, Nutrition, Dietics and Others); By Disease (Obesity, Diabetes, Autoimmune Disorder, Metabolic and Gastrointestinal Disorders, Cancer and Other Diseases); By Research Technology (Genomics, Proteomics and Metabolomics); By Distribution Channel (Retail Pharmacies, Online Pharmacies, Supermarkets and Hypermarket) - Forecast Year 2023 – 2030
Healthcare // Advanced Genetic Sequencing
The global human
microbiome market is foreseen to grow by 28.7%, from USD 162.84 Million in 2021
to USD 1225.71 Million in 2029. Rising industry-academia collaborations for
microbiome research, increasing focus on human microbiome therapeutics
development, human microbiome as a validated target for drug development is to drive
the market for the upcoming forecast period. However, Barriers in proving the
causal link between dysbiosis and diseases, negative clinical data will
adversely impact public perception of microbiomes remains one factor hindering
the market growth over the anticipated period.
Market Definition
What is Human microbiome?
Market Overview
The
human microbiome market search study helps to thoroughly understand the
current trend in the market competitive analysis of the players in the emerging
market. Moreover, the DRO in the Human microbiome market offers valuable
perspicuity and a current scenario for making the right decision. The research
study covers the eminent players in the market with a detailed analysis of the
company and a financial overview containing their net sales, business mix and
geographical reach It mainly focuses on the key developments of the
products/services offered by the company in recent years. Besides, we at Zettabyte
have the expertise to analyses the global Human microbiome market player's
competitive landscape helping the client comprehend their specific strategic
growth approaches.
Human
microbiome market study by "Zettabyte Analytics" offers details about
the market scope, market segmentation, technological advancement in the Human
microbiome market and highlights the optimistic, competitive landscape and
trends enduring over the years.
Major players in
the Human microbiome market include 4D Pharma Plc, Atlas Biomed, Biohm Health,
Biomx, Bione, Daytwo, Enterome, Evelo Biosciences, Inc., Ferring
Pharmaceuticals, Finch Therapeutics Group, Inc., Flightpath Biosciences, Inc.,
International Flavors & Fragrances Inc., Kaleido Biosciences, Inc., Luxia
Scientific, Metabiomics, Optibiotix Health Plc., Quantbiome, Inc. (Dba Ombre),
Second Genome Inc., Seres Therapeutics, Sun Genomics, Synlogic, Inc., Vedanta
Biosciences, Inc., Viome Life Sciences, Inc., Ysopia Bioscience.
COVID-19 Impact on Global Human
Microbiome Market
The global impact
of COVID-19 has lost millions of lives with a massive cost to the healthcare
system. Moreover, the treatment cost for patients with COVID-19 has also had a
financial impact globally. the impact of COVID-19 on the Human microbiome
market has forced the companies to change their sourcing, pricing, and
promotion strategies. the Human microbiome market players are seen focusing
more on optimizing the e-commerce networks with the rising innovations in the
digital sector, which are creating new business models for the healthcare industry
player.
Research Scope
The report
provides market value for the base year 2021 and a yearly forecast from 2022 to
2029 in revenue (USD Million/ Billion). the market for each segment is present
in North America, Europe, Asia Pacific, Latin America, Middle East &
Africa, and the regional basis for the forecast mentioned above.
Key industry
dynamics, regulatory scenarios, major material dynamics and Human microbiome
market future markets are analyzed to understand their impact on demand for the
forecast period. Growth rates have been estimated using correlation, regression
and time-series analysis.
Market Segmentation
For the purpose
of this report, the global human microbiome market segmented on the basis of product
type, disease type, application, type, and region:
Product Type Outlook:
On the basis of
product type, the market is segmented into probiotics, prebiotics, diagnostic
tests, drugs, other products.
Disease Type Outlook:
On the basis of
disease type, the market is segmented into infectious diseases, endocrine and
metabolic disorders, gastrointestinal diseases, cancer, other diseases.
Figure 1 Human microbiome Market By Disease
Type (Market Size And Forecast By Value - USD Million, 2021 & 2029)
Application Outlook:
On the basis of
application, the market is segmented into therapeutics, diagnostics.
Type Outlook:
On the basis of
type, the market is segmented into microbiome consortia transplantation (FMT),
peptide, live biotherapeutic product, others.
Regional Outlook (Revenue, USD million; 2021
& 2029)
|
Regional Outlook
(Revenue, USD million; 2018-2029) |
|
|
North America |
U.S. |
|
Canada |
|
|
Europe |
Germany |
|
U.K. |
|
|
France |
|
|
Spain |
|
|
Italy |
|
|
Rest of the Europe |
|
|
Asia Pacific |
India |
|
Japan |
|
|
China |
|
|
South Korea |
|
|
Australia |
|
|
Rest of Asia-Pacific |
|
|
Middle East & Africa |
UAE |
|
Saudi Arabia |
|
|
South Africa |
|
|
Rest of Middle East & Africa |
|
|
Latin America |
Brazil |
|
Mexico |
|
|
Argentina |
|
|
Rest of Latin America |
|
Â
Figure 2 Human microbiome Market: Regional Dynamics
Â
An exclusive human
microbiome market research report provides an in-depth analysis of the market
dynamics across five regions: North America, Europe, South America,
Asia-Pacific, Middle East, and Africa. Furthermore, the market has been
evaluated by utilizing diverse research methodologies and internal statistical model.
Companies Considered And Profiled In This
Market Study
The players
operating in the market have undertaken several strategies related to the
market in the period 2019-2021. some of the prominent players in the human
microbiome market include
·      4D Pharma Plc
·      Atlas Biomed
·      Biohm Health
·      Biomx
·      Bione
·      Daytwo
·      Enterome
·      Evelo Biosciences,
Inc.
·      Ferring
Pharmaceuticals
·      Finch Therapeutics
Group, Inc.
·      Flightpath
Biosciences, Inc.
·      International
Flavors & Fragrances Inc.
·      Kaleido
Biosciences, Inc.
·      Luxia Scientific
·      Metabiomics
·      Optibiotix Health
Plc.
·      Quantbiome, Inc.
(Dba Ombre)
·      Second Genome Inc.
·      Seres Therapeutics
·      Sun Genomics
·      Synlogic, Inc.
·      Vedanta
Biosciences, Inc.
·      Viome Life
Sciences, Inc.
·      Ysopia Bioscience
Global Human microbiome Market Report Scope
|
Historical
data |
2018 - 2020 |
|
Base
year for estimation |
2021 |
|
Forecast
period |
2022 - 2029 |
|
Market
size value in 2022 |
USD XX Billion |
|
Revenue
forecast in 2029 |
USD 1225.71 Million |
|
Growth
Rate |
CAGR of 28.7%
from 2022 to 2029 |
|
Quantitative
units |
Revenue in USD Million/Billion & CAGR
from 2022 to 2029 |
|
Report
coverage |
Revenue
forecast, company share, competitive landscape, growth factors, and trends |
|
Segments
covered |
Product Type, Disease Type, Application, Type |
|
Key
companies profiled |
Enterome, Seres
Therapeutics, 4D Pharma Plc |
|
Regional
Scope |
North America, Europe, Asia Pacific, Middle
East & Africa, Latin America |
|
Country
Scope |
U.S.,
Canada, Germany, U.K., France, Italy, Spain, India, Japan, China, Australia,
South Korea, Saudi Arabia, UAE, South Africa, Brazil, Mexico, Argentina |
|
Customization
scope |
Free report customization (equivalent to up
to 8 analysts’ working days) with purchase. Addition or alteration to
country, regional & segment scope. |
Â
Product Type Outlook (Revenue, USD Million/Billion;
2018-2029)
·      Probiotics
·      Prebiotics
·      Diagnostic Tests
·      Drugs
·      Other Products
Disease Type Outlook (Revenue, USD
Million/Billion; 2018-2029)
·      Infectious Diseases
·      Endocrine and
Metabolic Disorders
·      Gastrointestinal
Diseases
·      Cancer
·      Other Diseases
Application Outlook (Revenue, USD
Million/Billion; 2018-2029)
·      Therapeutics
·      Diagnostics
Type Outlook (Revenue, USD Million/Billion;
2018-2029)
·      Microbiome
Consortia Transplantation (FMT)
·      Peptide
·      Live Biotherapeutic
Product
·      Others
Regional Outlook (Revenue, USD Million/Billion;
2018-2029)
·      North America
o  U.S.
o  Canada
·      Europe
o  Germany
o  U.K.
o  France
o  Spain
o  Italy
o  Rest of the Europe
·      Asia Pacific
o  India
o  Japan
o  China
o  South Korea
o  Australia
o  Rest of
Asia-Pacific
·      Middle East &
Africa
o  UAE
o  Saudi Arabia
o  South Africa
o  Rest of Middle East
& Africa
·      Latin America
o  Brazil
o  Mexico
o  Argentina
o  Rest of Latin
America
Reasons to Buy the Report:
·      Save and reduce
time carrying out entry-level research by identifying the growth, size, leading
players and segments in the global human microbiome market
·      Highlights key
business priorities in order to guide the companies to reform their business
strategies and establish themselves in the wide geography.
·      The key findings
and recommendations highlight crucial progressive industry trends in the human
microbiome market, thereby allowing players to develop effective long-term
strategies in order to garner their market revenue.
·      Develop/modify
business expansion plans by using substantial growth offering developed and
emerging markets.
·      Scrutinize in-depth
global market trends and outlook coupled with the factors driving the market,
as well as those restraining the growth at a certain extent.
·      Enhance the
decision-making process by understanding the strategies that underpin
commercial interest with respect to products, segmentation and Types.
|
Chapter
1. Introduction |
|
|
1.1. Market Definition |
|
|
1.2. Research Scope |
|
|
1.2.1. Markets Covered |
|
|
1.2.2. Years Considered for
Study |
|
|
Chapter 2. Executive
Summary |
|
|
2.1. Summary Snapshot Market Size
and Forecast, 2018-2029 |
|
|
2.2. Human Microbiome Market Share by
Product Type, 2021 vs 2029 (USD Million) |
|
|
2.3. Human Microbiome Market Share by
Disease Type, 2021 vs 2029 (USD Million) |
|
|
2.4. Human Microbiome Market Share by
Application, 2021 vs 2029 (USD Million) |
|
|
2.5. Human Microbiome Market Share by
Type, 2021 vs 2029 (USD Million) |
|
|
2.6. Human Microbiome Market Share by
Region, 2021 vs 2029 (USD Million) |
|
|
Chapter 3. Key Insights |
|
|
Chapter 4. Human
Microbiome Market Segmentation & Impact Analysis |
|
|
4.1. Human Microbiome Market Indicators
Analysis |
|
|
4.1.1. Market Drivers
Analysis |
|
|
4.1.1.1. Rising
industry-academia collaborations for microbiome research |
|
|
4.1.1.2. Increasing
focus on human microbiome therapeutics development |
|
|
4.1.1.3. Human
microbiome as a validated target for drug development |
|
|
4.1.2. Market Restraint
Analysis |
|
|
4.1.2.1. Barriers in
proving the causal link between dysbiosis and diseases |
|
|
4.1.3. Market Opportunity
Analysis |
|
|
4.1.3.1. Increasing
collaborations between public-private organizations |
|
|
4.2. Regulatory Analysis |
|
|
4.2.1. North America |
|
|
4.2.1.1. U.S. |
|
|
4.2.1.2. Canada |
|
|
4.2.2. Europe |
|
|
4.2.3. Asia Pacific |
|
|
4.2.3.1. India |
|
|
4.2.3.2. Japan |
|
|
4.2.3.3. China |
|
|
4.3. Technological Insights |
|
|
4.4. COVID-19 Impact analysis on Human
Microbiome Market |
|
|
4.5. Porter’s Five Forces Analysis |
|
|
4.5.1. Bargaining Power of
Buyers/Consumers |
|
|
4.5.2. Bargaining Power of
Suppliers |
|
|
4.5.3. Threat of New Entrants |
|
|
4.5.4. Threat of Substitute
Products |
|
|
4.5.5. Intensity of Competitive
Rivalry |
|
|
4.6. Competitive Metric Space Analysis |
|
|
Chapter 5. Human
Microbiome Market, By Product Type (Market Size and Forecast by Value - USD
Million, 2018 - 2029) |
|
|
5.1. Human Microbiome Market, By Product
Type (Market Size and Forecast by Value - USD Million, 2021 & 2029) |
|
|
5.1.1. Probiotics |
|
|
5.1.1.1. Probiotics Market Estimates and Forecast,
2019-2029 (USD Million) |
|
|
5.1.1.2. Probiotics Market Estimates and Forecast,
By Region, 2019-2029 (USD Million) |
|
|
5.1.2. Prebiotics |
|
|
5.1.2.1. Prebiotics
Market Estimates and Forecast, 2019-2029 (USD Million) |
|
|
5.1.2.2. Prebiotics
Market Estimates and Forecast, By Region, 2019-2029 (USD Million) |
|
|
5.1.3. Diagnostic Tests |
|
|
5.1.3.1. Diagnostic
Tests Market Estimates and Forecast, 2019-2029 (USD Million) |
|
|
5.1.3.2. Diagnostic
Tests Market Estimates and Forecast, By Region, 2019-2029 (USD Million) |
|
|
5.1.4. Drugs |
|
|
5.1.4.1. Drugs
Market Estimates and Forecast, 2019-2029 (USD Million) |
|
|
5.1.4.2. Drugs
Market Estimates and Forecast, By Region, 2019-2029 (USD Million) |
|
|
5.1.5. Other Products |
|
|
5.1.5.1. Other
Products Market Estimates and Forecast, 2019-2029 (USD Million) |
|
|
5.1.5.2. Other Products
Market Estimates and Forecast, By Region, 2019-2029 (USD Million) |
|
|
Chapter 6. Human
Microbiome Market, By Disease Type (Market Size and Forecast by Value - USD
Million, 2018 - 2029) |
|
|
6.1. Human Microbiome Market, By
Disease Type (Market Size and Forecast by Value - USD Million, 2021 &
2029) |
|
|
6.1.1. Infectious Diseases |
|
|
6.1.1.1. Infectious Diseases Market Estimates and
Forecast, 2019-2029 (USD Million) |
|
|
6.1.1.2. Infectious Diseases Market Estimates and
Forecast, By Region, 2019-2029 (USD Million) |
|
|
6.1.2. Endocrine and Metabolic
Disorders |
|
|
6.1.2.1. Endocrine and Metabolic Disorders Market
Estimates and Forecast, 2019-2029 (USD Million) |
|
|
6.1.2.2. Endocrine and Metabolic Disorders Market
Estimates and Forecast, By Region, 2019-2029 (USD Million) |
|
|
6.1.3. Gastrointestinal
Diseases |
|
|
6.1.3.1.
Gastrointestinal Diseases Market Estimates and Forecast, 2019-2029 (USD
Million) |
|
|
6.1.3.2. Gastrointestinal
Diseases Market Estimates and Forecast, By Region, 2019-2029 (USD Million) |
|
|
6.1.4. Cancer |
|
|
6.1.4.1. Cancer
Market Estimates and Forecast, 2019-2029 (USD Million) |
|
|
6.1.4.2. Cancer
Market Estimates and Forecast, By Region, 2019-2029 (USD Million) |
|
|
6.1.5. Other Diseases |
|
|
6.1.5.1. Other
Diseases Market Estimates and Forecast, 2019-2029 (USD Million) |
|
|
6.1.5.2. Other
Diseases Market Estimates and Forecast, By Region, 2019-2029 (USD Million) |
|
|
Chapter 7. Human
Microbiome Market, By Application (Market Size and Forecast by Value - USD
Million, 2017 - 2029) |
|
|
7.1. Human Microbiome Market, By
Application (Market Size and Forecast by Value - USD Million, 2021 &
2029) |
|
|
7.1.1. Therapeutics |
|
|
7.1.1.1. Therapeutics Market Estimates and Forecast,
2019-2029 (USD Million) |
|
|
7.1.1.2. Therapeutics Market Estimates and Forecast,
By Region, 2019-2029 (USD Million) |
|
|
7.1.2. Diagnostics |
|
|
7.1.2.1. Diagnostics Market Estimates and Forecast,
2019-2029 (USD Million) |
|
|
7.1.2.2. Diagnostics Market Estimates and Forecast,
By Region, 2019-2029 (USD Million) |
|
|
Chapter 8. Human
Microbiome Market, By Type (Market Size and Forecast by Value - USD Million,
2018 - 2028) |
|
|
8.1. Human Microbiome Market, By Type
(Market Size and Forecast by Value - USD Million, 2021 & 2028) |
|
|
8.1.1. FMT |
|
|
8.1.1.1.
FMT Market Estimates and Forecast, 2018-2028 (USD Million) |
|
|
8.1.1.2. FMT Market Estimates and Forecast, By
Region, 2018-2028 (USD Million) |
|
|
8.1.2. Peptide |
|
|
8.1.2.1. Peptide Market Estimates and Forecast,
2018-2028 (USD Million) |
|
|
8.1.2.2. Peptide Market Estimates and Forecast, By
Region, 2018-2028 (USD Million) |
|
|
8.1.3. Live Biotherapeutic
Product |
|
|
8.1.3.1. Live
Biotherapeutic Product Market Estimates and Forecast, 2018-2028 (USD Million) |
|
|
8.1.3.2. Live
Biotherapeutic Product Market Estimates and Forecast, By Region, 2018-2028
(USD Million) |
|
|
8.1.4. Others |
|
|
8.1.4.1. Others Market
Estimates and Forecast, 2018-2028 (USD Million) |
|
|
8.1.4.2. Others
Market Estimates and Forecast, By Region, 2018-2028 (USD Million) |
|
|
Chapter 9. Human
Microbiome Market, By Region (Market Size and Forecast by Value - USD
Million, 2018 - 2029) |
|
|
9.1. Human Microbiome Market, By Region
(Market Size and Forecast by Value - USD Million, 2021 & 2029) |
|
|
9.2. North America |
|
|
9.2.1. North America Human
Microbiome Market, By Product Type, 2018-2029 (USD Million) |
|
|
9.2.2. North America Human
Microbiome Market, By Disease Type, 2018-2029 (USD Million) |
|
|
9.2.3. North America Human
Microbiome Market, By Application, 2018-2029 (USD Million) |
|
|
9.2.4. North America Human
Microbiome Market, By Type, 2018-2029 (USD Million) |
|
|
9.2.5. North America Human
Microbiome Market, By Country, 2018-2029 (USD Million) |
|
|
9.2.6. U.S. |
|
|
9.2.6.1. U.S.
Human Microbiome Market, By Product Type, 2018-2029 (USD Million) |
|
|
9.2.6.2. U.S.
Human Microbiome Market, By Disease Type, 2018-2029 (USD Million) |
|
|
9.2.6.3. U.S.
Human Microbiome Market, By Application, 2018-2029 (USD Million) |
|
|
9.2.6.4. U.S.
Human Microbiome Market, By Type, 2018-2029 (USD Million) |
|
|
9.2.7. Canada |
|
|
9.2.7.1. Canada
Human Microbiome Market, By Product Type, 2017-2029 (USD Million) |
|
|
9.2.7.2. Canada
Human Microbiome Market, By Disease Type, 2017-2029 (USD Million) |
|
|
9.2.7.3. Canada
Human Microbiome Market, By Application, 2017-2029 (USD Million) |
|
|
9.2.7.4. Canada
Human Microbiome Market, By Type, 2017-2029 (USD Million) |
|
|
9.3. Europe |
|
|
9.3.1. Europe Human Microbiome Market,
By Product Type, 2018-2029 (USD Million) |
|
|
9.3.2. Europe Human Microbiome
Market, By Disease Type, 2018-2029 (USD Million) |
|
|
9.3.3. Europe Human Microbiome
Market, By Application, 2018-2029 (USD Million) |
|
|
9.3.4. EuropeHuman Microbiome
Market, By Type, 2018-2029 (USD Million) |
|
|
9.3.5. Europe Human Microbiome
Market, By Country, 2018-2029 (USD Million) |
|
|
9.3.6. Germany |
|
|
9.3.6.1. Germany
Human Microbiome Market, By Product Type, 2018-2029 (USD Million) |
|
|
9.3.6.2. Germany
Human Microbiome Market, By Disease Type, 2018-2029 (USD Million) |
|
|
9.3.6.3. Germany
Human Microbiome Market, By Application, 2018-2029 (USD Million) |
|
|
9.3.6.4. Germany
Human Microbiome Market, By Type, 2018-2029 (USD Million) |
|
|
9.3.7. U.K. |
|
|
9.3.7.1. U.K. Human
Microbiome Market, By Product Type, 2017-2029 (USD Million) |
|
|
9.3.7.2. U.K.
Human Microbiome Market, By Disease Type, 2017-2029 (USD Million) |
|
|
9.3.7.3. U.K.
Human Microbiome Market, By Application, 2017-2029 (USD Million) |
|
|
9.3.7.4. U.K.
Human Microbiome Market, By Type, 2017-2029 (USD Million) |
|
|
9.3.8. France |
|
|
9.3.8.1. France
Human Microbiome Market, By Product Type, 2019-2029 (USD Million) |
|
|
9.3.8.2. France
Human Microbiome Market, By Disease Type, 2019-2029 (USD Million) |
|
|
9.3.8.3. France Human
Microbiome Market, By Application, 2019-2029 (USD Million) |
|
|
9.3.8.4. France
Human Microbiome Market, By Type, 2019-2029 (USD Million) |
|
|
9.3.9. Spain |
|
|
9.3.9.1. Spain
Human Microbiome Market, By Product Type, 2018-2029 (USD Million) |
|
|
9.3.9.2. Spain
Human Microbiome Market, By Disease Type, 2018-2029 (USD Million) |
|
|
9.3.9.3. Spain
Human Microbiome Market, By Application, 2018-2029 (USD Million) |
|
|
9.3.9.4. Spain
Human Microbiome Market, By Type, 2018-2029 (USD Million) |
|
|
9.3.10. Italy |
|
|
9.3.10.1. Italy Human
Microbiome Market, By Product Type, 2018-2029 (USD Million) |
|
|
9.3.10.2. Italy
Human Microbiome Market, By Disease Type, 2018-2029 (USD Million) |
|
|
9.3.10.3. Italy
Human Microbiome Market, By Application, 2018-2029 (USD Million) |
|
|
9.3.10.4. Italy
Human Microbiome Market, By Type, 2018-2029 (USD Million) |
|
|
9.3.11. Rest of Europe |
|
|
9.3.11.1. Rest of
Europe Human Microbiome Market, By Product Type, 2018-2029 (USD Million) |
|
|
9.3.11.2. Rest of
Europe Human Microbiome Market, By Disease Type, 2018-2029 (USD Million) |
|
|
9.3.11.3. Rest of
Europe Human Microbiome Market, By Application, 2018-2029 (USD Million) |
|
|
9.3.11.4. Rest of
Europe Human Microbiome Market, By Type, 2018-2029 (USD Million) |
|
|
9.4. Asia Pacific |
|
|
9.4.1. Asia Pacific Human Microbiome
Market, By Product Type, 2018-2029 (USD Million) |
|
|
9.4.2. Asia Pacific Human
Microbiome Market, By Disease Type, 2018-2029 (USD Million) |
|
|
9.4.3. Asia Pacific Human
Microbiome Market, By Application, 2018-2029 (USD Million) |
|
|
9.4.4. Asia Pacific Human
Microbiome Market, By Type, 2018-2029 (USD Million) |
|
|
9.4.5. Asia Pacific Human
Microbiome Market, By Country, 2018-2029 (USD Million) |
|
|
9.4.6. India |
|
|
9.4.6.1. India Human Microbiome Market, By
Product Type, 2018-2029 (USD Million) |
|
|
9.4.6.2. India Human
Microbiome Market, By Disease Type, 2018-2029 (USD Million) |
|
|
9.4.6.3. India
Human Microbiome Market, By Application, 2018-2029 (USD Million) |
|
|
9.4.6.4. India
Human Microbiome Market, By Type, 2018-2029 (USD Million) |
|
|
9.4.7. Japan |
|
|
9.4.7.1. Japan
Human Microbiome Market, By Product Type, 2017-2029 (USD Million) |
|
|
9.4.7.2. Japan
Human Microbiome Market, By Disease Type, 2017-2029 (USD Million) |
|
|
9.4.7.3. Japan
Human Microbiome Market, By Application, 2017-2029 (USD Million) |
|
|
9.4.7.4. Japan
Human Microbiome Market, By Type, 2017-2029 (USD Million) |
|
|
9.4.8. China |
|
|
9.4.8.1. China
Human Microbiome Market, By Product Type, 2019-2029 (USD Million) |
|
|
9.4.8.2. China
Human Microbiome Market, By Disease Type, 2019-2029 (USD Million) |
|
|
9.4.8.3. China Human Microbiome
Market, By Application, 2019-2029 (USD Million) |
|
|
9.4.8.4. China
Human Microbiome Market, By Type, 2019-2029 (USD Million) |
|
|
9.4.9. South Korea |
|
|
9.4.9.1. South Korea Human Microbiome
Market, By Product Type, 2018-2029 (USD Million) |
|
|
9.4.9.2. South
Korea Human Microbiome Market, By Disease Type, 2018-2029 (USD Million) |
|
|
9.4.9.3. South
Korea Human Microbiome Market, By Application, 2018-2029 (USD Million) |
|
|
9.4.9.4. South
Korea Human Microbiome Market, By Type, 2018-2029 (USD Million) |
|
|
9.4.10. Australia |
|
|
9.4.10.1. Australia
Human Microbiome Market, By Product Type, 2018-2029 (USD Million) |
|
|
9.4.10.2.
Australia Human Microbiome Market, By Disease Type, 2018-2029 (USD Million) |
|
|
9.4.10.3.
Australia Human Microbiome Market, By Application, 2018-2029 (USD Million) |
|
|
9.4.10.4.
Australia Human Microbiome Market, By Type, 2018-2029 (USD Million) |
|
|
9.4.11. Rest of Asia Pacific |
|
|
9.4.11.1. Rest of
Asia Pacific Human Microbiome Market, By Product Type, 2018-2029 (USD
Million) |
|
|
9.4.11.2. Rest of
Asia Pacific Human Microbiome Market, By Disease Type, 2018-2029 (USD
Million) |
|
|
9.4.11.3. Rest of
Asia Pacific Human Microbiome Market, By Application, 2018-2029 (USD Million) |
|
|
9.4.11.4. Rest of
Asia Pacific Human Microbiome Market, By Type, 2018-2029 (USD Million) |
|
|
9.5. Middle East & Africa |
|
|
9.5.1. Middle East & Africa
Human Microbiome Market, By Product Type, 2018-2029 (USD Million) |
|
|
9.5.2. Middle East &
AfricaHuman Microbiome Market, By Disease Type, 2018-2029 (USD Million) |
|
|
9.5.3. Middle East & Africa
Human Microbiome Market, By Application, 2018-2029 (USD Million) |
|
|
9.5.4. Middle East & Africa
Human Microbiome Market, By Type, 2018-2029 (USD Million) |
|
|
9.5.5. Middle East & Africa
Human Microbiome Market, By Country, 2018-2029 (USD Million) |
|
|
9.5.6. UAE |
|
|
9.5.6.1. UAE
Human Microbiome Market, By Product Type, 2018-2029 (USD Million) |
|
|
9.5.6.2. UAE
Human Microbiome Market, By Disease Type, 2018-2029 (USD Million) |
|
|
9.5.6.3. UAE
Human Microbiome Market, By Application, 2018-2029 (USD Million) |
|
|
9.5.6.4. UAE
Human Microbiome Market, By Type, 2018-2029 (USD Million) |
|
|
9.5.7. Saudi Arabia |
|
|
9.5.7.1. Saudi
Arabia Human Microbiome Market, By Product Type, 2017-2029 (USD Million) |
|
|
9.5.7.2. Saudi
Arabia Human Microbiome Market, By Disease Type, 2017-2029 (USD Million) |
|
|
9.5.7.3. Saudi
Arabia Human Microbiome Market, By Application, 2017-2029 (USD Million) |
|
|
9.5.7.4. Saudi Arabia
Human Microbiome Market, By Type, 2017-2029 (USD Million) |
|
|
9.5.8. South Africa |
|
|
9.5.8.1. South Africa
Human Microbiome Market, By Product Type, 2019-2029 (USD Million) |
|
|
9.5.8.2. South
Africa Human Microbiome Market, By Disease Type, 2019-2029 (USD Million) |
|
|
9.5.8.3. South
Africa Human Microbiome Market, By Application, 2019-2029 (USD Million) |
|
|
9.5.8.4. South
Africa Human Microbiome Market, By Type, 2019-2029 (USD Million) |
|
|
9.5.9. Rest of Middle East
& Africa |
|
|
9.5.9.1. Rest of
Middle East & Africa Human Microbiome Market, By Product Type, 2018-2029
(USD Million) |
|
|
9.5.9.2. Rest of
Middle East & Africa Human Microbiome Market, By Disease Type, 2018-2029
(USD Million) |
|
|
9.5.9.3. Rest of
Middle East & Africa Human Microbiome Market, By Application, 2018-2029
(USD Million) |
|
|
9.5.9.4. Rest of
Middle East & Africa Human Microbiome Market, By Type, 2018-2029 (USD
Million) |
|
|
9.6. Latin America |
|
|
9.6.1. Latin America Human
Microbiome Market, By Product Type, 2018-2029 (USD Million) |
|
|
9.6.2. Latin America Human Microbiome
Market, By Disease Type, 2018-2029 (USD Million) |
|
|
9.6.3. Latin America Human
Microbiome Market, By Application, 2018-2029 (USD Million) |
|
|
9.6.4. Latin America Human Microbiome
Market, By Type, 2018-2029 (USD Million) |
|
|
9.6.5. Latin America Human
Microbiome Market, By Country, 2018-2029 (USD Million) |
|
|
9.6.6. Brazil |
|
|
9.6.6.1. Brazil
Human Microbiome Market, By Product Type, 2018-2029 (USD Million) |
|
|
9.6.6.2. Brazil
Human Microbiome Market, By Disease Type, 2018-2029 (USD Million) |
|
|
9.6.6.3. Brazil
Human Microbiome Market, By Application, 2018-2029 (USD Million) |
|
|
9.6.6.4. Brazil
Human Microbiome Market, By Type, 2018-2029 (USD Million) |
|
|
9.6.7. Mexico |
|
|
9.6.7.1. Mexico
Human Microbiome Market, By Product Type, 2018-2029 (USD Million) |
|
|
9.6.7.2. Mexico Human
Microbiome Market, By Disease Type, 2018-2029 (USD Million) |
|
|
9.6.7.3. Mexico
Human Microbiome Market, By Application, 2018-2029 (USD Million) |
|
|
9.6.7.4. Mexico
Human Microbiome Market, By 10A, 2018-2029 (USD Million) |
|
|
9.6.8. Argentina |
|
|
9.6.8.1.
Argentina Human Microbiome Market, By Product Type, 2019-2029 (USD Million) |
|
|
9.6.8.2. Argentina
Human Microbiome Market, By Disease Type, 2019-2029 (USD Million) |
|
|
9.6.8.3.
Argentina Human Microbiome Market, By Application, 2019-2029 (USD Million) |
|
|
9.6.8.4.
Argentina Human Microbiome Market, By Type, 2019-2029 (USD Million) |
|
|
9.6.9. Rest of Latin America |
|
|
9.6.9.1. Rest of Latin
America Human Microbiome Market, By Product Type, 2018-2029 (USD Million) |
|
|
9.6.9.2. Rest of
Latin America Human Microbiome Market, By Disease Type, 2018-2029 (USD
Million) |
|
|
9.6.9.3. Rest of
Latin America Human Microbiome Market, By Application, 2018-2029 (USD
Million) |
|
|
9.6.9.4. Rest of
Latin America Human Microbiome Market, By Type, 2018-2029 (USD Million) |
|
|
Chapter 10. Competitive Landscape |
|
|
10.1. Market Revenue Share by
Manufacturers |
|
|
10.2. Competitor’s Positioning |
|
|
10.3. Strategy Benchmarking |
|
|
10.3.1. Partnership &
Agreement |
|
|
10.3.2. New Product
Development |
|
|
10.3.3. Mergers & Acquisitions |
|
|
10.3.4. Investment &
Expansion |
|
|
10.4. Vendor Landscape |
|
|
10.4.1. Distributors |
|
|
10.4.2. North America |
|
|
10.4.3. Europe |
|
|
10.4.4. Asia Pacific |
|
|
10.4.5. Middle East & Africa |
|
|
10.4.6. Latin America |
|
|
10.5. Zettabyte Analytics Insights for
Competitive Landscape |
|
|
Chapter 11. Company
Profiles |
|
|
11.1. 4D Pharma Plc |
|
|
11.1.1. Company Overview |
|
|
11.1.2. Products Offered |
|
|
11.1.3. Financials |
|
|
11.1.4. Recent
Development |
|
|
11.2. Atlas Biomed |
|
|
11.2.1. Company Overview |
|
|
11.2.2. Products Offered |
|
|
11.2.3. Financials |
|
|
11.2.4. Recent
Development |
|
|
11.3. Biohm Health |
|
|
11.3.1. Company Overview |
|
|
11.3.2. Products Offered |
|
|
11.3.3. Financials |
|
|
11.3.4. Recent Development |
|
|
11.4. Biomx |
|
|
11.4.1. Company Overview |
|
|
11.4.2. Products Offered |
|
|
11.4.3. Financials |
|
|
11.4.4. Recent
Development |
|
|
11.5. Bione |
|
|
11.5.1. Company Overview |
|
|
11.5.2. Products Offered |
|
|
11.5.3. Financials |
|
|
11.5.4. Recent
Development |
|
|
11.6. Daytwo |
|
|
11.6.1. Company Overview |
|
|
11.6.2. Products Offered |
|
|
11.6.3. Financials |
|
|
11.6.4. Recent
Development |
|
|
11.7. Enterome |
|
|
11.7.1. Company Overview |
|
|
11.7.2. Products Offered |
|
|
11.7.3. Financials |
|
|
11.7.4. Recent Development |
|
|
11.8. Evelo Biosciences, Inc. |
|
|
11.8.1. Company Overview |
|
|
11.8.2. Products Offered |
|
|
11.8.3. Financials |
|
|
11.8.4. Recent
Development |
|
|
11.9. Ferring Pharmaceuticals |
|
|
11.9.1. Company Overview |
|
|
11.9.2. Products Offered |
|
|
11.9.3. Financials |
|
|
11.9.4. Recent
Development |
|
|
11.10. Finch Therapeutics Group, Inc. |
|
|
11.10.1. Company Overview |
|
|
11.10.2. Products Offered |
|
|
11.10.3. Financials |
|
|
11.10.4. Recent
Development |
|
|
11.11. Flightpath Biosciences, Inc. |
|
|
11.11.1. Company Overview |
|
|
11.11.2. Products Offered |
|
|
11.11.3. Financials |
|
|
11.11.4. Recent
Development |
|
|
11.12. International Flavors &
Fragrances Inc. |
|
|
11.12.1. Company Overview |
|
|
11.12.2. Products Offered |
|
|
11.12.3. Financials |
|
|
11.12.4. Recent
Development |
|
|
11.13. Kaleido Biosciences, Inc. |
|
|
11.13.1. Company Overview |
|
|
11.13.2. Products Offered |
|
|
11.13.3. Financials |
|
|
11.13.4. Recent
Development |
|
|
11.14. Luxia Scientific |
|
|
11.14.1. Company Overview |
|
|
11.14.2. Products Offered |
|
|
11.14.3. Financials |
|
|
11.14.4. Recent Development |
|
|
11.15. Metabiomics |
|
|
11.15.1. Company Overview |
|
|
11.15.2. Products Offered |
|
|
11.15.3. Financials |
|
|
11.15.4. Recent
Development |
|
|
11.16. Optibiotix Health Plc. |
|
|
11.16.1. Company Overview |
|
|
11.16.2. Products Offered |
|
|
11.16.3. Financials |
|
|
11.16.4. Recent
Development |
|
|
11.17. Quantbiome, Inc. (Dba Ombre) |
|
|
11.17.1. Company Overview |
|
|
11.17.2. Products Offered |
|
|
11.17.3. Financials |
|
|
11.17.4. Recent
Development |
|
|
11.18. Second Genome Inc. |
|
|
11.18.1. Company Overview |
|
|
11.18.2. Products Offered |
|
|
11.18.3. Financials |
|
|
11.18.4. Recent
Development |
|
|
13.19. Seres Therapeutics |
|
|
13.19.1. Company Overview |
|
|
13.19.2. Products Offered |
|
|
13.19.3. Financials |
|
|
13.19.4. Recent
Development |
|
|
13.20. Sun Genomics |
|
|
13.20.1. Company Overview |
|
|
13.20.2. Products Offered |
|
|
13.20.3. Financials |
|
|
13.20.4. Recent Development |
|
|
13.21. Synlogic, Inc. |
|
|
13.21.1. Company Overview |
|
|
13.21.2. Products Offered |
|
|
13.21.3. Financials |
|
|
13.21.4. Recent
Development |
|
|
13.22. Vedanta Biosciences, Inc. |
|
|
13.22.1. Company Overview |
|
|
13.22.2. Products Offered |
|
|
13.22.3. Financials |
|
|
13.22.4. Recent
Development |
|
|
13.23. Viome Life Sciences, Inc. |
|
|
13.23.1. Company Overview |
|
|
13.23.2. Products Offered |
|
|
13.23.3. Financials |
|
|
13.23.4. Recent
Development |
|
|
13.24. Ysopia Bioscience |
|
|
13.24.1. Company Overview |
|
|
13.24.2. Products Offered |
|
|
13.24.3. Financials |
|
|
13.24.4. Recent
Development |
|
|
Chapter 12. Research
Methodology |
|
|
12.1. Research Sources |
|
|
12.1.1. Primary |
|
|
12.1.2. Secondary |
|
|
12.12. Market Size Estimation |
|
|
Chapter 13. Appendix |
|
|
13.1. Discussion guide |
|
|
13.2. Knowledge Store:
Zettabyte Analytics Subscription Portal |
|
|
13.3. Available
Customizations |
|
|
13.4. Associated
Zettabyte Analytics Reports |
|
|
List of Tables |
|
|
Table 1 |
Human Microbiome Market,
By Product Type (Market Size and Forecast by Value - USD Million, 2021 &
2029) |
|
Table 2 |
Probiotics Market
Estimates and Forecast, 2019-2029 (USD Million) |
|
Table 3 |
Probiotics Market
Estimates and Forecast, By Region, 2019-2029 (USD Million) |
|
Table 4 |
Prebiotics Market
Estimates and Forecast, 2019-2029 (USD Million) |
|
Table 5 |
Prebiotics Market
Estimates and Forecast, By Region, 2019-2029 (USD Million) |
|
Table 6 |
Human Microbiome Market,
By Disease Type (Market Size and Forecast by Value - USD Million, 2021 &
2029) |
|
Table 7 |
Infectious Diseases
Market Estimates and Forecast, 2019-2029 (USD Million) |
|
Table 8 |
Infectious Diseases
Market Estimates and Forecast, By Region, 2019-2029 (USD Million) |
|
Table 9 |
Human Microbiome Market,
By Application (Market Size and Forecast by Value - USD Million, 2021 &
2029) |
|
Table 10 |
Therapeutics Market
Estimates and Forecast, 2019-2029 (USD Million) |
|
Table 11 |
Therapeutics Market
Estimates and Forecast, By Region, 2019-2029 (USD Million) |
|
Table 12 |
Diagnostics Market
Estimates and Forecast, 2019-2029 (USD Million) |
|
Table 13 |
Diagnostics Market
Estimates and Forecast, By Region, 2019-2029 (USD Million) |
|
Table 14 |
Market Estimates and Forecast, 2019-2029
(USD Million) |
|
Table 15 |
Market Estimates and Forecast, By Region,
2019-2029 (USD Million) |
|
Table 16 |
Human Microbiome Market,
By Type (Market Size and Forecast by Value - USD Million, 2021 & 2029) |
|
Table 17 |
FMT Market Estimates and
Forecast, 2019-2029 (USD Million) |
|
Table 18 |
FMT Market Estimates and
Forecast, By Region, 2019-2029 (USD Million) |
|
Table 19 |
Peptide Market Estimates
and Forecast, 2019-2029 (USD Million) |
|
Table 20 |
Peptide Market Estimates
and Forecast, By Region, 2019-2029 (USD Million) |
|
Table 21 |
North America Human
Microbiome Market, By Product Type, 2018-2029 (USD Million) |
|
Table 22 |
North America Human
Microbiome Market, By Disease Type, 2018-2029 (USD Million) |
|
Table 23 |
North America Human
Microbiome Market, By Application, 2018-2029 (USD Million) |
|
Table 24 |
North America Human
Microbiome Market, By Type, 2018-2029 (USD Million) |
|
Table 25 |
North America Human
Microbiome Market, By Country, 2018-2029 (USD Million) |
|
Table 26 |
U.S. Human Microbiome
Market, By Product Type, 2018-2029 (USD Million) |
|
Table 27 |
U.S. Human Microbiome
Market, By Disease Type, 2018-2029 (USD Million) |
|
Table 28 |
U.S. Human Microbiome
Market, By Application, 2018-2029 (USD Million) |
|
Table 29 |
U.S. Human Microbiome
Market, By Type, 2018-2029 (USD Million) |
|
Table 30 |
Canada Human Microbiome
Market, By Product Type, 2018-2029 (USD Million) |
|
Table 31 |
Canada Human Microbiome
Market, By Disease Type, 2018-2029 (USD Million) |
|
Table 32 |
Canada Human Microbiome
Market, By Application, 2018-2029 (USD Million) |
|
Table 33 |
Canada Human Microbiome
Market, By Type, 2018-2029 (USD Million) |
|
Table 34 |
Europe Human Microbiome
Market, By Product Type, 2018-2029 (USD Million) |
|
Table 35 |
Europe Human Microbiome
Market, By Disease Type, 2018-2029 (USD Million) |
|
Table 36 |
Europe Human Microbiome
Market, By Application, 2018-2029 (USD Million) |
|
Table 37 |
EuropeHuman Microbiome
Market, By Type, 2018-2029 (USD Million) |
|
Table 38 |
Europe Human Microbiome
Market, By Country, 2018-2029 (USD Million) |
|
Table 39 |
Germany Human Microbiome
Market, By Product Type, 2018-2029 (USD Million) |
|
Table 40 |
Germany Human Microbiome
Market, By Disease Type, 2018-2029 (USD Million) |
|
Table 41 |
Germany Human Microbiome
Market, By Application, 2018-2029 (USD Million) |
|
Table 42 |
Germany Human Microbiome
Market, By Type, 2018-2029 (USD Million) |
|
Table 43 |
U.K. Human Microbiome
Market, By Product Type, 2018-2029 (USD Million) |
|
Table 44 |
U.K. Human Microbiome
Market, By Disease Type, 2018-2029 (USD Million) |
|
Table 45 |
U.K. Human Microbiome
Market, By Application, 2018-2029 (USD Million) |
|
Table 46 |
U.K. Human Microbiome
Market, By Type, 2018-2029 (USD Million) |
|
Table 47 |
France Human Microbiome
Market, By Product Type, 2018-2029 (USD Million) |
|
Table 48 |
France Human Microbiome
Market, By Disease Type, 2018-2029 (USD Million) |
|
Table 49 |
France Human Microbiome
Market, By Application, 2018-2029 (USD Million) |
|
Table 50 |
France Human Microbiome
Market, By Type, 2018-2029 (USD Million) |
|
Table 51 |
Spain Human Microbiome
Market, By Product Type, 2018-2029 (USD Million) |
|
Table 52 |
Spain Human Microbiome
Market, By Disease Type, 2018-2029 (USD Million) |
|
Table 53 |
Spain Human Microbiome
Market, By Application, 2018-2029 (USD Million) |
|
Table 54 |
Spain Human Microbiome
Market, By Type, 2018-2029 (USD Million) |
|
Table 55 |
Italy Human Microbiome
Market, By Product Type, 2018-2029 (USD Million) |
|
Table 56 |
Italy Human Microbiome
Market, By Disease Type, 2018-2029 (USD Million) |
|
Table 57 | |